Shinkei Kenkyu no Shinpo Volume 49, Issue 3 (June 2005)

Biomarkers for Alzheimer's disease Takeshi Kawarabayashi 1 , Mikio Shoji 1 1Department of Neurology, Okayama University Graduate School of Medicine and Dentistry Keyword: アルツハイマー病 , 脳脊髄液 , アミロイドβ蛋白 , タウ , MCI pp.411-422
Published Date 2005/6/10
  • Abstract
  • Look Inside

Recent progress of the treatment for Alzheimer's disease(AD)demands the accuracy in the early diagnosis of AD. To determine if a patient with mild cognitive impairment(MCI)has incipient AD, is also becoming the noteworthy issue. Three cerebrospinal fluid(CSF)biomarkers;β-amyloid42(Aβ42), total tau(t-tau)and phosphorylated tau(p-tau)have been evaluated in numerous scientific papers. Measurement of Aβ42 and t-tau in the CSF is useful for the diagnosis of AD, especially when they are combined. Studies showed that measurement of p-tau improves early and differential diagnosis of AD. They are also useful markers to identify incipient AD in MCI cases. Aβ oligomer in CSF shows interesting results though the data is preliminary. Plasma Aβ seems to be a useful marker to evaluate the risk of AD though it has low specifity for diagnosis of AD. Early diagnosis of AD using these biomarkers may contribute to develop drugs aimed at targeting the degenerating processes of AD.

Copyright © 2005, Igaku-Shoin Ltd. All rights reserved.


49巻3号 (2005年6月)
電子版ISSN 1882-1243 印刷版ISSN 0001-8724 医学書院